A Stimulatory Thyrotropin Receptor Antibody (M22) and Thyrotropin Increase Interleukin-6 Expression and Secretion in Graves' Orbital Preadipocyte Fibroblasts
Authors:
- 1 January 2010
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 20 (1) , 59-65
Abstract
Background: Patients with Graves' ophthalmopathy (GO) have circulating autoantibodies directed against the thyrotropin receptor (TSHR) and elevated levels of the proinflammatory cytokine interleukin-6 (IL-6) in both serum and orbital tissues. We hypothesized that these autoantibodies might increase IL-6 expression and secretion in preadipocyte fibroblasts and adipocytes from patients with GO, and thus directly impact the clinical activity of the disease. Methods: IL-6 mRNA levels were measured in cultures of GO orbital preadipocytes (n = 3) treated during adipocyte differentiation with a monoclonal stimulatory TSHR antibody (M22; 10 ng/mL), IL-6 (1 ng/mL), or TSH (10 U/L). Additionally, levels of IL-6 protein secretion were assessed after adipocyte differentiation in orbital cultures exposed to TSH or M22 for 24 or 48 hours (n = 8). IL-6 mRNA levels were also measured in orbital adipose tissue specimens from well-characterized GO patients (n = 9) and normal individuals (n = 9). Results: Treatment of GO orbital preadipocyte cultures with IL-6, TSH, or M22 during adipocyte differentiation resulted in increased IL-6 mRNA levels (3.1-fold, 2.9-fold, and 2.7-fold, respectively; p < 0.05). Treatment of orbital cultures with M22 or TSH after adipocyte differentiation enhanced the release of IL-6 protein into the medium at both 24 and 48 hours for TSH (mean 1.9- and 2.3-fold; p = 0.002 and 0.015, respectively) and at 48 hours for M22 (mean 2.0-fold; p = 0.005). In addition, we found mean IL-6 mRNA levels to be significantly increased in GO orbital adipose tissue specimens (10-fold; p < 0.01), primarily attributable to high levels in three of the four patients with clinical activity scores ≥5. Conclusions: Both TSH and M22 increase IL-6 expression in orbital preadipocyte fibroblasts and IL-6 secretion by mature adipocytes. These results suggest that circulating TSHR autoantibodies in GO might play a direct role in the clinical activity of the disease.Keywords
This publication has 59 references indexed in Scilit:
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Biological Effects of Thyrotropin Receptor Activation on Human Orbital PreadipocytesInvestigative Ophthalmology & Visual Science, 2006
- Differentiation of Human Orbital Preadipocyte Fibroblasts Induces Expression of Functional Thyrotropin ReceptorThe Journal of Clinical Endocrinology & Metabolism, 1999
- Glycosaminoglycans in Thyroid Eye DiseaseThyroid®, 1998
- The Thyrotropin Receptor in Thyroid Eye DiseaseThyroid®, 1998
- High Circulating IL-6 Level in Graves' OphthalmopathyAutoimmunity, 1997
- Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts.Journal of Clinical Investigation, 1994
- Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissueThe Lancet, 1993
- Detection and localization of cytokine immunoreactivity in retro‐ocular connective tissue in Graves' opthalmopathyEuropean Journal of Clinical Investigation, 1993
- Detection of TSH Receptor RNA in Cultured Fibroblasts from Patients with Graves' Ophthalmopathy and Pretibial DermopathyThyroid®, 1993